ABG
SLDB icon

Ally Bridge Group’s Solid Biosciences SLDB Stock Holding History

Ally Bridge Group’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Sell
255,959
-511,015
-67% -$3.87M 2.26% 15
2026
Q1 		$5.52M Buy
766,974
+353,349
+85% +$2.27M 4.46% 8
2025
Q4 		$2.33M Sell
413,625
-135,557
-25% -$735K 2.43% 16
2025
Q3 		$3.39M Sell
549,182
-174,818
-24% -$1.02M 2.06% 18
2025
Q2 		$3.53M Buy
+724,000
New +$2.56M 2.93% 16

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ally Bridge Group's SLDB Position: Q2 2026 in Review

Ally Bridge Group reduced its Solid Biosciences (SLDB) stake by 67% in Q2 2026, selling an estimated $3.87M and leaving 255,959 shares worth $2.56M. The position accounts for 2.26% of the portfolio, ranked #15.

Ally Bridge Group first reported a position in SLDB in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.52M in Q1 2026. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Ally Bridge Group held 255,959 shares of Solid Biosciences worth $2.56M as of Q2 2026.
  • Ally Bridge Group sold 511,015 Solid Biosciences shares in Q2 2026, an estimated $3.87M.
  • Solid Biosciences made up 2.26% of Ally Bridge Group's portfolio in Q2 2026, its #15 holding.
  • Ally Bridge Group first reported a position in Solid Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Ally Bridge Group's Solid Biosciences position peaked at $5.52M in Q1 2026.
  • 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.